• Katherine O'Flaherty, OoWin HanWHBurnet Institute Myanmar, Yangon, Myanmar., Sophie G Zaloumis, Julia C Cutts, AungKyaw ZayarKZBurnet Institute Myanmar, Yangon, Myanmar., TheinMyat MonMMBurnet Institute Myanmar, Yangon, Myanmar., Damien R Drew, Zahra Razook, Alyssa E Barry, Naanki Parischa, ZawNyi NyiNNBurnet Institute Myanmar, Yangon, Myanmar., ThuHtin KyawHKBurnet Institute Myanmar, Yangon, Myanmar., Aung Thi, HtayWai Yan MinWYMBurnet Institute Myanmar, Yangon, Myanmar., SoeAung PaingAPBurnet Institute Myanmar, Yangon, Myanmar., Julie A Simpson, James G Beeson, Paul A Agius, and FowkesFreya J IFJIBurnet Institute for Medical Research and Public Health, Melbourne, Australia. freya.fowkes@burnet.edu.au.Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne.
• Burnet Institute for Medical Research and Public Health, Melbourne, Australia.
• Bmc Med. 2021 May 28; 19 (1): 121.

BackgroundIn the Greater Mekong Subregion (GMS), current malaria surveillance strategies rely on a network of village health volunteers (VHVs) reporting the results of rapid diagnostic tests (RDTs), known to miss many asymptomatic infections. Integration of more sensitive diagnostic molecular and serological measures into the VHV network may improve surveillance of residual malaria transmission in hard-to-reach areas in the region and inform targeted interventions and elimination responses. However, data on residual malaria transmission that would be captured by these measures in the VHV-led testing and treatment surveillance network in the GMS is unknown.MethodsA total of 114 VHVs were trained to collect dried blood spots from villagers undergoing routine RDTs as part of VHV-led active and passive case detection from April 2015 to June 2016. Samples were subjected to molecular testing (quantitative polymerase chain reaction [qPCR]) to determine Plasmodium falciparum and P. vivax infection and serological testing (against P. falciparum and P. vivax antigens) to determine exposure to P. falciparum and P. vivax.ResultsOver 15 months, 114 VHVs performed 32,194 RDTs and collected samples for molecular (n = 13,157) and serological (n = 14,128) testing. The prevalence of molecular-detectable P. falciparum and P. vivax infection was 3.2% compared to the 0.16% prevalence of Plasmodium spp. by RDT, highlighting the large burden of infections undetected by standard surveillance. Peaks in anti-P. falciparum, but not P. vivax, merozoite IgG seroprevalence coincided with seasonal P. falciparum transmission peaks, even in those with no molecularly detectable parasites. At the individual level, antibody seropositivity was associated with reduced odds of contemporaneous P. falciparum (OR for PfCSP 0.51 [95%CI 0.35, 0.76], p = 0.001, PfAMA1 0.70 [95%CI 0.52, 0.93], p = 0.01, and PfMSP2 0.81 [95%CI 0.61, 1.08], p = 0.15), but not P. vivax infection (OR PvAMA1 1.02 [95%CI 0.73, 1.43], p = 0.89) indicating a potential role of immunity in protection against molecular-detectable P. falciparum parasitaemia.ConclusionsWe demonstrated that integration and implementation of sample collection for molecular and serological surveillance into networks of VHV servicing hard-to-reach populations in the GMS is feasible, can capture significant levels of ongoing undetected seasonal malaria transmission and has the potential to supplement current routine RDT testing. Improving malaria surveillance by advancing the integration of molecular and serological techniques, through centralised testing approaches or novel point-of-contact tests, will advance progress, and tracking, towards malaria elimination goals in the GMS.

20 keywords...

hide…